Non-peptide

SLU-PP-332

Also known as

SLU PP 332 · SLUPP332 · SLU-PP332 · SLU-PP 332 · ERR pan-agonist (SLU-PP-332) · ERR agonist exercise-mimetic discussion compound · Saint Louis University PP-332 · CAS 303760-60-3

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	An experimental small molecule activating estrogen-related receptors involved in cellular energy machinery. It is not a peptide or estrogen.
Why people look it up	Easier cardio, workout capacity and fat loss. Exercise-mimetic mouse findings explain the interest but do not establish human benefit or an exercise replacement.

Notes

An experimental small molecule, despite the peptide label. It activates estrogen-related receptors (ERRs), which regulate energy machinery. Exercise-like gene activity in mice explains the exercise-mimetic idea. It is not estrogen or an exercise replacement. Billon et al. — Synthetic ERR agonist and exercise capacity (Animal context · Accessed 2026-09-30)

SLU-PP-332 is an experimental small molecule discussed for easier cardio, workout capacity and fat loss. Accounts range from better stamina to no change, with heat, fatigue and disrupted sleep recurring in the opened reports. Mouse research explains the interest; it does not establish human effectiveness or safety.

Source context — Billon et al. — Synthetic ERR agonist and exercise capacity: Abstract and figure captions only; full PMC body hit reCAPTCHA. Cells/mice; 30 mg/kg IP exposure points cannot establish human half-life. Authors disclose Myonid stock holdings.

What people notice

Workout capacity	Some report better workouts, energy or focus, sometimes with sweating and fatigue. Other accounts notice nothing at very different labeled amounts.
Scale change and crashes	One oral course described faster loss while also increasing activity and maintaining a deficit. Brief energy followed by exhaustion appears in other reports.

Notes

Easier workouts are the clearest theme in these positive accounts. Complete-Bid2858 described better workouts, focus, sweating and fatigue. SDMFsoldier separately reported energy over four weeks at 250 mcg SubQ on weekdays. These are individual accounts. SLU PP 332 — My Experience (Ongoing) (Community discussion · Accessed 2026-09-30)

Oral success and oral failure both appear at very different amounts. AZTimZ reported benefit with 500 mcg oral capsules but none with 25 mg tablets from another product. A separate commenter reported no change after a month of 50 mg sublingual and a previous two months at 25 mg. The older 200 mg null anecdote remains distinct from the 200 mcg account. Dosing experience with SLU PP 332? (Community discussion · Accessed 2026-09-30) · SLU-PP-332 experience (dosage test) (Personal report · Accessed 2026-09-30)

Fat-loss reports also change diet and activity. exbrowser422 reported faster scale loss amid a calorie deficit and increased activity. Other accounts report no change. Warmth, endurance and weight loss are different outcomes. SLU-PP-332 experience (dosage test) (Personal report · Accessed 2026-09-30) · SLU-PP-332: My experience (Personal report · Accessed 2026-09-30)

Two to three hours of energy in one liquid account; about five hours in another. Kooky_Examination_52 described 200 mcg twice daily (400 mcg/day), brief energy/euphoria, then exhaustion. Whon-T separately estimated five hours of effect; that reply does not identify route. acmack78 reported no initial rush but profound fatigue 3–5 hours after 6 mg oral liquid, while also using retatrutide. SLU PP 332 Initial Experience (Community discussion · Accessed 2026-09-30) · Fatigue? (Personal report · Accessed 2026-09-30)

Source context — SLU PP 332 — My Experience (Ongoing): Self-reported oral tablet amounts; baseline fatigue, training, deficit and product not verified. SubQ responder is a different author. Guide promotion present; preparation advice excluded.

Source context — Dosing experience with SLU PP 332?: Vendor-review site; some users have promo badges. Routes ambiguous except explicit capsules/tablets. No source authenticity or prevalence inferred.

Source context — SLU-PP-332 experience (dosage test): Unverified oral tablets; changing amount, calorie deficit, steps and expectations. Promotional guide bot present. One author across multiple sections remains one account.

Source context — SLU-PP-332: My experience: One unblinded oral tablet report; unverified content and body-composition measurements. Post date not inferred from relative timestamp.

Source context — SLU PP 332 Initial Experience: Vendor-named subreddit and influencer mention; severe diet/training confounding, no exposure measurement. Route not inferred from subreddit; OP swallowing-liquid reply inspected. Whon-T route unspecified.

Source context — Fatigue?: Oral liquid, retatrutide co-use, surplus and training confound fatigue. Preparation, vendor, pricing and syringe instructions excluded. Replies' glycogen explanation is speculation.

Doses people talk about

Lower oral accounts	200 mcg each morning for 21 days, then 300 mcg, gave one user no benefit. Another used 2 mg/day for two weeks, then 2 mg three times daily, totaling 6 mg/day.
Multi-milligram oral accounts	One user began at 60 mg pre-workout, later using 40 mg morning + 20 mg pre-workout, then 20 mg mornings and finally three times weekly because fatigue persisted. These are competing experiences, not a dose ladder.
Under-skin charts	Separate charts include 250–500 mcg/day, 500 mcg–1.5 mg/day, or 1.25–2.5 mg/day split twice daily. They are unverified patterns, without an established oral conversion.
Extreme report	One author explicitly reported 200 mg morning + 200 mg noon, totaling 400 mg/day, with fatigue and longer sleep. SLU's route was unclear; the stated SubQ route concerned NAD+.

Notes

Oral tablets: 200 mcg versus multi-milligram courses. Human-Lemon7620 reported 200 mcg each morning for 21 days, then 300 mcg, without benefit. exbrowser422 used 2 mg/day for two weeks, then 2 mg three times daily (6 mg/day) for two weeks; 10 mg at once preceded exhaustion after three days, followed by alternate-day 10 mg use. SLU-PP-332: My experience (Personal report · Accessed 2026-09-30) · SLU-PP-332 experience (dosage test) (Personal report · Accessed 2026-09-30)

Oral 20–60 mg reports do not settle the dose debate. Complete-Bid2858 began at 60 mg before training, tried 40 mg morning plus 20 mg pre-workout, then 20 mg each morning and eventually 20 mg three times weekly because fatigue persisted. Other preserved talk spans 1–10+ mg/day, 20–100 mg and 50–400 mg experiments; these are competing claims, not one effective range. SLU PP 332 — My Experience (Ongoing) (Community discussion · Accessed 2026-09-30)

SubQ talk uses different numbers. The preserved discussion lists 250–500 mcg/day initially, 500 mcg–1.5 mg/day, and separate 1.25–2.5 mg/day totals split twice daily; one gradual account went 0.25→0.5→0.75 mg. These unverified patterns are not validated regimens. Counterclaims about 0.2–1 mg receptor saturation also lack measured human exposure.

Capsules, liquid and injections are separate discussions. Community use includes swallowed tablets/capsules, bulk powder, sublingual liquid and experimental SubQ injections. Mouse abdominal injections are a laboratory route. Different formulations and routes cannot be compared by labeled amount alone.

An extreme 400 mg/day account needs its own label. Character_Medium_484 explicitly confirmed milligrams: 200 mg morning plus 200 mg noon. They reported fatigue and longer sleep after earlier 100 mg and microgram attempts without attributable benefit. SLU's route is unclear; the stated SubQ route belongs to NAD+. Mouse-to-human calculations do not create a clinical dose. Any experience with high-dose SLU-PP-332? (Community discussion · Accessed 2026-09-30)

Source context — SLU-PP-332: My experience: One unblinded oral tablet report; unverified content and body-composition measurements. Post date not inferred from relative timestamp.

Source context — Any experience with high-dose SLU-PP-332?: 400 mg/day is explicitly confirmed milligrams but SLU route unspecified. NAD+ is the SubQ compound in OP. Multiple co-exposures, changed food and training; no clinical dose or causation.

Half-life, onset & duration

Felt onset	One 60 mg oral account reports about 30 minutes; separate SubQ lore says 20–60 minutes. Route and outcome differ.
Felt duration	One oral-liquid account describes 2–3 hours of energy then exhaustion. Another estimates five hours without identifying route; a separate 6 mg oral-liquid user felt profound fatigue after 3–5 hours.
Half-life	A half-life claim of about 1.5 hours circulates without measured human clearance here. Mouse tissue samples at 2 and 6 hours are not a human half-life.

Notes

Some report a first-workout change; others notice nothing for weeks. Complete-Bid2858 described an effect within roughly 30 minutes of oral 60 mg. Separate SubQ lore describes warmth or readiness for cardio at 20–60 minutes. The 2 mg oral course had no clear effect in weeks 1–2; the 200 mcg account remained unchanged at 21 days. Route and outcome matter. SLU PP 332 — My Experience (Ongoing) (Community discussion · Accessed 2026-09-30) · SLU-PP-332: My experience (Personal report · Accessed 2026-09-30)

Kooky_Examination_52 OP lines 18–32; oral-liquid clarification lines 155–168; Whon-T duration/onset lines 188–210; Ampegged sleep/liquid-route replies lines 82–122. SLU PP 332 Initial Experience (Community discussion · Accessed 2026-09-30)

A 1.5-hour half-life claim circulates; human elimination remains unmeasured here. A Reddit reply gives 1.5 hours without a study, species or route. Earlier notes describe the same number as serum/tissue shorthand. Neither supplies measured human clearance. Twice- or three-times-daily habits, energy crashes and tissue detection are not half-life measurements. So what's all this Fuss about SLU-PP-332? (Secondhand community claim · Accessed 2026-09-30)

Animal exposure points are not human timing. The 2023 study sampled plasma/muscle at 2 and 6 hours after 30 mg/kg abdominal injection and used 50 mg/kg twice daily in mice. These points do not measure human half-life or validate retail amounts. Billon et al. — Synthetic ERR agonist and exercise capacity (Animal context · Accessed 2026-09-30)

Source context — SLU-PP-332: My experience: One unblinded oral tablet report; unverified content and body-composition measurements. Post date not inferred from relative timestamp.

Source context — So what's all this Fuss about SLU-PP-332?: 1.5-hour reply gives no study, species, route or measurement; cannot authenticate human elimination. OP promotes an affiliate code; prescriptive dose answers rejected.

Cycles people discuss

Blocks and breaks	2–4-week check-ins, 4–8-week runs, daily use and activity-linked blocks appear. Breaks range from 1–2 weeks to equal time off, without an established washout.
Fatigue-driven changes	Some stop for days or reduce use to three sessions weekly after fatigue. Five-on/two-off also appears, without establishing safety.

Notes

Two to four weeks for a check-in; four to eight weeks for longer runs. These are preserved community patterns, alongside daily open-ended use and activity-linked blocks. Breaks range from 1–2 weeks to equal 4–8-week time off. No established washout or restart standard follows from them.

Fatigue changes some people's schedule. The 10 mg oral author stopped for the rest of a week after three difficult days. The 20 mg author shifted to three sessions weekly after accumulating fatigue. Five-on/two-off appears in earlier discussion; none establishes safety. SLU-PP-332 experience (dosage test) (Personal report · Accessed 2026-09-30) · SLU PP 332 — My Experience (Ongoing) (Community discussion · Accessed 2026-09-30)

Stacks

Metabolic combinations	5-Amino-1MQ, MOTS-c, NAD+/NMN/NR and incretin drugs recur. Their combined use does not establish synergy or safety.
Other cut stacks	Cardarine, SARMs, stimulant fat burners and BAM15 also appear. Some discuss switching to SLU-PP-915 rather than combining two ERR compounds.

Notes

Stacks make attribution harder. Prior discussion pairs SLU with 5-Amino-1MQ, MOTS-c, NAD+/NMN/NR, incretins, Cardarine, SARMs or stimulant fat burners; BAM15 appears too. These combinations do not establish synergy or safety. Interest in switching to oral 915 rather than combining two ERR compounds is a community preference, not a recommendation.

Top dual stack: SLU-PP-332 + 5-Amino-1MQ — most-named biohacker pairing (ERR oxidative program + NNMT / NAD-adjacent metabolic talk). [community]

Triple metabolic: SLU + 5-Amino-1MQ + MOTS-c appears in synergy write-ups (mitochondrial / AMPK adjacency); attribution gets muddy fast. [community]

GLP-1 era stacks: Retatrutide or other incretins for appetite deficit + SLU for “oxidative tone / muscle fuel” theory — no published combo data. [community]

NAD support: NMN, NR, or NAD+ injectables listed alongside for mitochondrial narrative synergy. [community]

Watch for

Heat, fatigue and heart rate	Sweating, crashes, sleep disruption, nausea and increased hunger are reported. One 20 mg/day oral account described resting heart rate of 95–100 bpm amid extensive co-use.
Injection and exposure uncertainty	Site pain and uncertain contents complicate reports. Claims about oral absorption, fatty meals or changing routes do not establish measured human exposure; long-term safety remains unresolved.

Notes

Heat, fatigue, sleep disruption and heart-rate changes deserve attention. Reports include sweating, evening crashes and waking early. Khandum reported resting HR 95–100 bpm during 20 mg/day oral use and about 76 after stopping, amid extensive co-use. That change does not prove fat burning. Earlier accounts also mention nausea, stomach discomfort and increased hunger. SLU PP 332 Initial Experience (Community discussion · Accessed 2026-09-30) · My SLUPP Experience (Personal report · Accessed 2026-09-30)

Injection pain and uncertain contents complicate the comparison. One 500 mcg injected account described substantial site pain and sweating without another clear benefit. Product identity, amount and formulation remain unverified; a clear-looking liquid or a stronger label does not establish exposure. Long-term human safety remains unresolved. SLU-PP-332's oral bioavailability (the lack thereof) (Community discussion · Accessed 2026-09-30)

Switching routes can change the story without proving why. Jvbatisti reported no oral benefit, then easier training after switching to injections, with later sleep trouble and resting HR 95–105. Supplier involvement and AAS co-use limit this comparison; another responder saw no route difference. Neither settles oral absorption. My SLU-PP-332 Log / Experience (Community discussion · Accessed 2026-09-30)

Food, absorption workarounds and 915 remain disputed. Morning/fasted and pre-cardio use occur beside taking it with food for comfort. Fatty-meal claims, enteric capsules and sublingual delivery have no demonstrated human absorption fix here. A forum author challenges the circulated 45% oral-bioavailability number; confidently repeating a percentage does not verify it. SLU-PP-332's oral bioavailability (the lack thereof) (Community discussion · Accessed 2026-09-30)

Source context — My SLUPP Experience: 20 mg/day oral testimonial with AAS, retatrutide, HGH, methylene blue and telmisartan; vendor-review environment. Raised HR does not prove absorption, fat burning or safety.

Source context — SLU-PP-332's oral bioavailability (the lack thereof): Chemical reasoning and disputed 45% claim are community interpretations, not inspected human PK or independently audited Wikipedia history. Commercial formulations discussed; recipes excluded.

Source context — My SLU-PP-332 Log / Experience: AAS co-use; named supplier praised and replies by a lab account; no proof of sponsorship or independence. Injectable switch explicit, later IM reference. Severe HR report not proof of SLU causation.

Full notes

What SLU-PP-332 actually is

An experimental small molecule, despite the peptide label. It activates estrogen-related receptors (ERRs), which regulate energy machinery. Exercise-like gene activity in mice explains the exercise-mimetic idea. It is not estrogen or an exercise replacement. Animal context
Capsules, liquid and injections are separate discussions. Community use includes swallowed tablets/capsules, bulk powder, sublingual liquid and experimental SubQ injections. Mouse abdominal injections are a laboratory route. Different formulations and routes cannot be compared by labeled amount alone. Community

What people hope to gain

Easier workouts are the clearest theme in these positive accounts. Complete-Bid2858 described better workouts, focus, sweating and fatigue. SDMFsoldier separately reported energy over four weeks at 250 mcg SubQ on weekdays. These are individual accounts. Reddit
Fat-loss reports also change diet and activity. exbrowser422 reported faster scale loss amid a calorie deficit and increased activity. Other accounts report no change. Warmth, endurance and weight loss are different outcomes. Personal report Personal report

Doses: amounts people report

Oral tablets: 200 mcg versus multi-milligram courses. Human-Lemon7620 reported 200 mcg each morning for 21 days, then 300 mcg, without benefit. exbrowser422 used 2 mg/day for two weeks, then 2 mg three times daily (6 mg/day) for two weeks; 10 mg at once preceded exhaustion after three days, followed by alternate-day 10 mg use. Personal report Personal report
Oral 20–60 mg reports do not settle the dose debate. Complete-Bid2858 began at 60 mg before training, tried 40 mg morning plus 20 mg pre-workout, then 20 mg each morning and eventually 20 mg three times weekly because fatigue persisted. Other preserved talk spans 1–10+ mg/day, 20–100 mg and 50–400 mg experiments; these are competing claims, not one effective range. Reddit Community
SubQ talk uses different numbers. The preserved discussion lists 250–500 mcg/day initially, 500 mcg–1.5 mg/day, and separate 1.25–2.5 mg/day totals split twice daily; one gradual account went 0.25→0.5→0.75 mg. These unverified patterns are not validated regimens. Counterclaims about 0.2–1 mg receptor saturation also lack measured human exposure. Community
An extreme 400 mg/day account needs its own label. Character_Medium_484 explicitly confirmed milligrams: 200 mg morning plus 200 mg noon. They reported fatigue and longer sleep after earlier 100 mg and microgram attempts without attributable benefit. SLU's route is unclear; the stated SubQ route belongs to NAD+. Mouse-to-human calculations do not create a clinical dose. Reddit

Half-life: what the numbers mean

A 1.5-hour half-life claim circulates; human elimination remains unmeasured here. A Reddit reply gives 1.5 hours without a study, species or route. Earlier notes describe the same number as serum/tissue shorthand. Neither supplies measured human clearance. Twice- or three-times-daily habits, energy crashes and tissue detection are not half-life measurements. Reddit Community

Onset: when a change is noticed

Some report a first-workout change; others notice nothing for weeks. Complete-Bid2858 described an effect within roughly 30 minutes of oral 60 mg. Separate SubQ lore describes warmth or readiness for cardio at 20–60 minutes. The 2 mg oral course had no clear effect in weeks 1–2; the 200 mcg account remained unchanged at 21 days. Route and outcome matter. Reddit Community Personal report

Duration: how long the experience lasts

Two to three hours of energy in one liquid account; about five hours in another. Kooky_Examination_52 described 200 mcg twice daily (400 mcg/day), brief energy/euphoria, then exhaustion. Whon-T separately estimated five hours of effect; that reply does not identify route. acmack78 reported no initial rush but profound fatigue 3–5 hours after 6 mg oral liquid, while also using retatrutide. Reddit Personal report
Lasting body-composition benefits are not established. Repeated-use weight reports do not measure one dose's duration or persistence after stopping. An older comparison describes 10 mg oral 915 as steadier and 500 mcg SubQ 332 as sharper, but it changes both molecule and route and remains an unverified individual comparison. Community

Cycles and breaks people discuss

Two to four weeks for a check-in; four to eight weeks for longer runs. These are preserved community patterns, alongside daily open-ended use and activity-linked blocks. Breaks range from 1–2 weeks to equal 4–8-week time off. No established washout or restart standard follows from them. Community
Fatigue changes some people's schedule. The 10 mg oral author stopped for the rest of a week after three difficult days. The 20 mg author shifted to three sessions weekly after accumulating fatigue. Five-on/two-off appears in earlier discussion; none establishes safety. Personal report Reddit Community

Good to know

Heat, fatigue, sleep disruption and heart-rate changes deserve attention. Reports include sweating, evening crashes and waking early. Khandum reported resting HR 95–100 bpm during 20 mg/day oral use and about 76 after stopping, amid extensive co-use. That change does not prove fat burning. Earlier accounts also mention nausea, stomach discomfort and increased hunger. Reddit Personal report Community
Injection pain and uncertain contents complicate the comparison. One 500 mcg injected account described substantial site pain and sweating without another clear benefit. Product identity, amount and formulation remain unverified; a clear-looking liquid or a stronger label does not establish exposure. Long-term human safety remains unresolved. Reddit Community

What the community arguments add

Oral success and oral failure both appear at very different amounts. AZTimZ reported benefit with 500 mcg oral capsules but none with 25 mg tablets from another product. A separate commenter reported no change after a month of 50 mg sublingual and a previous two months at 25 mg. The older 200 mg null anecdote remains distinct from the 200 mcg account. Eroids Personal report Community
Switching routes can change the story without proving why. Jvbatisti reported no oral benefit, then easier training after switching to injections, with later sleep trouble and resting HR 95–105. Supplier involvement and AAS co-use limit this comparison; another responder saw no route difference. Neither settles oral absorption. MESO-Rx
Food, absorption workarounds and 915 remain disputed. Morning/fasted and pre-cardio use occur beside taking it with food for comfort. Fatty-meal claims, enteric capsules and sublingual delivery have no demonstrated human absorption fix here. A forum author challenges the circulated 45% oral-bioavailability number; confidently repeating a percentage does not verify it. Community Reddit
Stacks make attribution harder. Prior discussion pairs SLU with 5-Amino-1MQ, MOTS-c, NAD+/NMN/NR, incretins, Cardarine, SARMs or stimulant fat burners; BAM15 appears too. These combinations do not establish synergy or safety. Interest in switching to oral 915 rather than combining two ERR compounds is a community preference, not a recommendation. Community Community

Supporting context: the mouse work

Animal exposure points are not human timing. The 2023 study sampled plasma/muscle at 2 and 6 hours after 30 mg/kg abdominal injection and used 50 mg/kg twice daily in mice. These points do not measure human half-life or validate retail amounts. Animal context
The fat-loss rationale is preclinical. The metabolic study reports reduced fat accumulation and altered fuel use in obese mice. Its captions describe 28-day and 15-day experiments; normal-chow mice did not show improved glucose metabolism. These findings do not validate the community's human outcomes. Animal context
Pill-development language is easy to overread. The University of Florida's 2023 report described refining the molecule toward a pill before human trials. It also reported 70% longer and 45% farther mouse running and 12% weight loss in obese mice. These are animal results, not promised human benefits. Official context
The 915 paper describes a different orally active molecule. Its preserved abstract describes parent 332 as lacking oral bioavailability in the mouse program and 915 as chemically distinct and orally active. That does not establish human absorption of either product or a human route-conversion rule. Animal context